-
Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, Grifols, Regeneron
25 Apr 2024 17:00 GMT
… Sumitomo Dainippon Pharma Co., Ltd., Merck & Co., Inc., Mallinckrodt … Sumitomo Dainippon Pharma Co., Ltd., Merck & Co., Inc., Mallinckrodt … Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., …
-
Merck Announces First-Quarter 2024 Financial Results
25 Apr 2024 10:54 GMT
… through business development. Merck completed the acquisition of … code 4164932.
About Merck
At Merck, known as MSD … collaborations and licensing arrangements.
MERCK & CO., INC.
… the prior termination of the Sanofi-Pasteur MSD joint venture.
…
-
Type 2 Diabetes Market Detailed In New Research Report 2024-2031 | Novo Nordisk, Sanofi, Eli Lilly and Company, Merck.
25 Apr 2024 08:54 GMT
… are
Novo Nordisk, Sanofi, Eli Lilly and Company, Merck & Co., Inc …
-
Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight | Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & Co., Novo Nordisk, Eli Lilly and Company, Biocon
23 Apr 2024 17:00 GMT
… Market - Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & … such as Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & … Drugs Companies
Sanofi, AstraZeneca, Pfizer, Johnson & Johnson, Novartis, Merck & …
-
Immuno-oncology Drugs Market to See Huge Growth by 2031:Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc
11 Apr 2024 10:16 GMT
… Ltd.
◘ Merck & Co. Inc.
◘ Novartis AG
◘ Pfizer Inc.
◘ Sanofi
◘ Ferring B …
-
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
10 Apr 2024 19:34 GMT
… to its broader valency. Merck’s 15-valent and Pfizer … accessible for infants, with Merck initially targeting this market.
… Needham highlights that Pfizer, Merck, and Sanofi SA SNY are currently … 31-valent vaccine. Regarding Merck’s V116, Vaxcyte predicts …
-
Myocardial Infarction Market is Booming Worldwide 2031 |Bayer AG, Johnson & Johnson Services Inc, Sanofi S.A, Pfizer Inc
08 Apr 2024 10:40 GMT
…
◘ Johnson & Johnson Services Inc.
◘ Sanofi S.A.
◘ Novartis International AG … Ingelheim International GmbH
◘ Pfizer Inc.
◘ Merck KGaA.
Market Segmentation:
By Drug …
-
Spatial AI biomarker startup Nucleai raises $14 million led by Merck’s VC arm
03 Apr 2024 12:13 GMT
… corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported … of Google Ventures, Bill Maris, Sanofi Ventures, the corporate venture capital … arm of Sanofi, Debiopharm, Fosun RZ Capital, Vertex …
-
Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
03 Apr 2024 11:16 GMT
… venture capital arm of Merck KGaA, Darmstadt, Germany, … investors include Section 32, Sanofi, Vertex Ventures, M Ventures … corporate venture capital arm of Merck KGaA, Darmstadt, Germany. … vitality and sustainability of Merck KGaA, Darmstadt, Germany…
-
Dementia Drugs Market to See Booming Growth 2024-2031 | Novartis AG, Sanofi S.A, Eisai, Inc, Janssen Pharmaceuticals,Inc
01 Apr 2024 09:40 GMT
… AG
◘ Sanofi S.A.
◘ AstraZeneca GmbH
◘ F. Hoffmann-La Roche
◘ Merck …